Source:http://linkedlifedata.com/resource/pubmed/id/11509930
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2001-8-17
|
pubmed:abstractText |
This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1). From October 1994 to July 1999, 20 patients (median age 9.9 years, range 0.11-16.2) were treated in six centers. Eighteen had de novo AML and two had secondary AML. According to BFM criteria, 10 were classified as standard- and 10 as high-risk patients, respectively. The median time from diagnosis to CR1 and from diagnosis to Auto-HSCT were 1.1 months (range 0.8-1.6) and 4.3 months (range 3.1-6.2), respectively. Purging with either mafosfamide (three) or in vivo interleukin-2 (four) was performed in seven of 20 patients. Melphalan was administered at a dosage of 150-220 mg/m(2) (median 180). Median total number of nucleated cells infused was 2.5 x 10(8)/kg (range 1.1-8.9). The myeloablative regimen was well tolerated with no toxic death, veno-occlusive disease or life-threatening complications. All patients had hematopoietic recovery in a median time of 27 days for neutrophils and 44 days for platelets. Eight of 20 patients relapsed after a median time of 7.2 months from transplant (range 5.7-15.9). Six of them died (five of progression of disease and one of sepsis) while the remaining two patients are alive in CR2. The 3-year cumulative probability of survival and event-free-survival (EFS) is 62% and 56%, respectively. This study showed that in pediatric patients with AML consolidation of CR1 with high-dose melphalan allows survival and EFS to be obtained comparable to other auto-HSCT or chemotherapy published series with a potential sparing effect both on duration of treatment (with respect to chemotherapy) and on long-term side-effects (with respect to auto-HSCT with TBI or busulfan containing regimens).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/mafosfamide
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0268-3369
|
pubmed:author |
pubmed-author:BagnuloSS,
pubmed-author:CaniggiaMM,
pubmed-author:CesaroSS,
pubmed-author:Italian Pediatric Group for Bone Marrow Transplantation,
pubmed-author:LaninoEE,
pubmed-author:LocatelliFF,
pubmed-author:MeloniGG,
pubmed-author:MessinaCC,
pubmed-author:PessionAA,
pubmed-author:PillonMM,
pubmed-author:ProgliaAA
|
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
131-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11509930-Adolescent,
pubmed-meshheading:11509930-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11509930-Bone Marrow Purging,
pubmed-meshheading:11509930-Child,
pubmed-meshheading:11509930-Child, Preschool,
pubmed-meshheading:11509930-Combined Modality Therapy,
pubmed-meshheading:11509930-Cyclophosphamide,
pubmed-meshheading:11509930-Female,
pubmed-meshheading:11509930-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11509930-Humans,
pubmed-meshheading:11509930-Infant,
pubmed-meshheading:11509930-Interleukin-2,
pubmed-meshheading:11509930-Italy,
pubmed-meshheading:11509930-Leukemia, Myeloid, Acute,
pubmed-meshheading:11509930-Male,
pubmed-meshheading:11509930-Melphalan,
pubmed-meshheading:11509930-Patient Selection,
pubmed-meshheading:11509930-Retrospective Studies,
pubmed-meshheading:11509930-Survival Rate,
pubmed-meshheading:11509930-Transplantation, Autologous
|
pubmed:year |
2001
|
pubmed:articleTitle |
High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
|
pubmed:affiliation |
Clinica di Oncoematologia Pediatrica, Dipartimento di Pediatria, Università di Padova, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|